Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study The ...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab ...

Ocrelizumab and rituximab, both anti-CD20 B-cell monoclonal antibodies, differ in molecular structure and safety profiles, impacting MS treatment outcomes. Retrospective data from the University of ...

Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 ...

--TG Therapeutics, Inc., announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI, the company’ s anti-CD20 monoclonal antibody, in people with relapsing forms ...

CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...

Philadelphia, November 16, 2023 – Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME). Their anti-tumor functions include recognizing tumor-associated antigens, ...

Over the past few years, there has been considerable progress defining the potential role of B cells in normal immunity and also in the pathogenesis of autoimmune conditions including rheumatoid ...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® ...